Transcriptomic behavior of genes associated with chromo some 21 aneuploidies in early embryo development

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Sanchez-Ribas, I
  • Diaz-Gimeno, P
  • Sebastian-Leon, P
  • Mercader, A
  • Quinonero, A
  • Ballesteros, A
  • Dominguez, F

Grupos

Abstract

Objective: To analyze how chromosome 21 (HSA21) ploidy affects global gene expression of early human blastocysts. Design: Prospective study. Setting: University-affiliated in vitro fertilization clinic. Patient(s): A total of 26 high-quality donated embryos from in vitro fertilization (IVF) patients: trisomy 21 (n = 8), monosomy 21 (n = 10), and euploid (n = 8) blastocysts. Intervention(s): None. Main Outcome Measure(s): Blastocyst transcriptome changes and its associated functions. Result(s): Trisomy 21, monosomy 21, and euploid blastocysts were classified by comparative genomic hybridization. The global transcriptome of whole blastocysts was analyzed with small cell number RNA sequencing, and they were compared to understand the gene expression behavior at early development and its implications for embryo implantation. We identified 1,232 differentially expressed genes (false discovery rate <0.05) in monosomy 21 compared with euploid blastocysts associated with dysregulated functions in embryo development as the Rap1 signaling pathway. Curiously, Down syndrome in early development revealed fewer transcriptomic changes than expected. In addition, Down syndrome gene expression in neonates, children, and adults revealed that the number of deregulated genes increases across life stages from blastocysts to adults, suggesting a potential dosage-compensation mechanism for human chromosome 21. Conclusion(s): At the transcriptomic level, early development in Down syndrome is mainly dosage compensated. However, monosomy 21 is strongly transcriptionally affected because early development involving main functions is associated with embryo implantation. ((C) 2019 by American Society for Reproductive Medicine.)

Datos de la publicación

ISSN/ISSNe:
0015-0282, 1556-5653

FERTILITY AND STERILITY  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
991-
PubMed:
30922649
Factor de Impacto:
2,311 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 10

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Blastocyst transcriptome; chromosome 21 abnormalities; Down Syndrome in early development; HSA21 gene expression; trisomy and monosomy 21

Campos de Estudio

Proyectos y Estudios Clínicos

ESTUDIO DE LA ENFERMEDAD METASTASICA EN EL TEJIDO OVARICO CRIOPRESERVADO DE MUJERES CON CANCER DE MAMA

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI08/90483 . INSTITUTO DE SALUD CARLOS III . 2009

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL

CD11/00292 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORELL

CD12/00568 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

CONTRATO POST FSE (RIO HORTEGA)

CM13/00191 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

CD15/00058 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2016

TRAMIENTO COMBINADO DE VITAMINA D CON AGNRH SOBRE EL CRECIMIENTO DE LOS MIOMAS UTERINOS

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI15/00312 . INSTITUTO DE SALUD CARLOS III . 2016

Alternativas para la Preservacion de la fertilidad en pacientes con leucemia aguda. Maduracion in vivo mediante xenotransplante.

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

GRISOLIAP/2018/029 . CONSELLERIA DE EDUCACION . 2018

Estudio de las modificaciones epigenéticas como posibles dianas terapéuticas para tratar los miomas uterinos.

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI18/00323 . INSTITUTO DE SALUD CARLOS III . 2019

ESTUDIO CLÍNICO PILOTO PARA EVALUAR EL EFECTO DE LA VITAMINA D SOBRE EL TAMAÑO DE LOS MIOMAS EN MUJERES CON DEFICIENCIA DE VITAMINA D.

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

IIS-COL-2018-01 . 2019

ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR SEGURIDAD Y EFICACIA DE ELAGOLIX EN PARTICIPANTES CON DOLOR MODERADO O SEVERO ASOCIADO A ENDOMETRIOSIS.

Investigador Principal: VICENTE PAYÁ AMATE

M12-671

Cita

Compartir